https://investorplace.com/2024/02/why-is-morphosys-mor-stock-up-50-today/?utm_source=financialcontent&utm_medium=quotes
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.
morphosysstocktodayinvestorplace
https://www.clinicaltrialsarena.com/news/newsmorphosys-initiates-phase-iii-trial-of-mor208-bendamustine-for-dlbcl-5834056/
German biotechnology firm MorphoSys has initiated patient enrolment for the Phase III part of the Phase II/III B-MIND clinical trial of MOR208 and bendamustine...
phase iii trialmorphosysinitiatesbendamustine
https://www.technologynetworks.com/proteomics/news/morphosys-and-the-university-of-melbourne-file-new-patent-applications-in-mor103-program-201463
MOR103 HuCAL antibody against human GM-CSF is currently in development for the treatment of rheumatoid arthritis.
patent applicationsmorphosysuniversitymelbournefile
https://www.technologynetworks.com/immunology/news/morphosys-and-chemicon-enter-into-licensing-agreement-for-research-antibodies-201444
MorphoSys' Antibodies by Design unit will develop antibodies against targets identified and supplied by Chemicon.
licensing agreementmorphosyschemiconenterresearch
https://www.technologynetworks.com/biopharma/news/morphosys-strengthens-patent-position-on-lead-program-mor103-201561
The new patent covers MorphoSys's HuCAL antibody against GM-CSF as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in...
lead programmorphosyspatentpositiontechnology